Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Topologically designed antibody candidates for SARS-CoV-2 and cancer therapies

A recent study presented topologically engineered fragment crystallizable-fusion proteins and antibodies as therapeutic options for diseases like human coronaviruses infections and cancers.

25 Mar 2022

New implantable biotechnology produces and releases CAR-T cells for attacking tumors

Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed an implantable biotechnology that produces and releases CAR-T cells for attacking cancerous tumors.

24 Mar 2022

Vaccine-induced antibody response to SARS-CoV-2 Omicron variant in patients with B cell malignancies with and without active B cell-targeted therapy

Researchers have determined the effect of booster immunization on the levels of antibodies generated, against SARS-CoV-2 variants, including the Omicron strain, in cancer patients with or without active B cell-targeted therapy.

22 Mar 2022

Trial reveals effectiveness of axi-cel as first-line treatment for high-risk lymphoma

Results from the ZUMA-12 trial led by researchers at The University of Texas MD Anderson Cancer Center showed that first-line treatment with axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor (CAR) T cell therapy, achieved a high rate of complete response in patients with high-risk large B-cell lymphoma (LBCL).

21 Mar 2022

Study finds high rates of cancer among men living with HIV

Researchers with Case Western Reserve University have found that there are nearly twice as many men with cancer among men living with HIV (MLWH) compared to men who do not have the human immunodeficiency virus.

17 Mar 2022

Study links phthalates to higher incidence of specific childhood cancers

In a first-of-its-kind study, research from the University of Vermont Cancer Center has linked phthalates, commonly called the "everywhere chemical," to higher incidence of specific childhood cancers.

16 Mar 2022

Zentalis contributes $1 million to SU2C Catalyst program for research into targeted cancer therapeutics

Stand Up To Cancer and Zentalis Pharmaceuticals, Inc. today announced that Zentalis will contribute $1 million to the SU2C Catalyst program to support research that investigates the use of certain small molecule inhibitors for treating a variety of cancer types.

15 Mar 2022

Multi-institutional teams awarded grant support from the Starr Cancer Consortium

Two multi-institutional teams led by Weill Cornell Medicine scientists have been awarded grant support from the Starr Cancer Consortium. Both grants will fund work applying new technologies to develop more detailed knowledge of tumor biology, with one team focusing on Hodgkin lymphoma and the other on the purity of tumor samples on pathology slides.

10 Mar 2022

Most cancer patients develop antibodies after receiving COVID-19 vaccine, study shows

Cancer patients who have compromised immune systems due to their disease or therapy remain at high risk for COVID-19 infection.

10 Mar 2022

Study explores immune escape mutations caused by prolonged viral shedding in immunocompromised COVID-19 patient

A new study examined a unique case of extended viral shedding in an immunocompromised patient that produced a series of SARS-CoV-2 immune escape mutations over a seven-month period.

8 Mar 2022

New, highly promising strategy to overcome a key cause of cancer deaths

A research team led by scientists at Albert Einstein College of Medicine has devised a novel and highly promising strategy for overcoming a key cause of cancer deaths: the ability of cancer cells to thrive in the face of chemotherapy drugs designed to destroy them.

7 Mar 2022

World Trade Center responders have increased levels of mutations that escalate blood cancer risk

Scientists from Vanderbilt-Ingram Cancer Center (VICC) collaborated with researchers from New York to determine that 9/11 first responders to the World Trade Center have increased levels of mutations that escalate their risk for blood cancers or cardiovascular disease, according to a study published March 7 in Nature Medicine.

7 Mar 2022

Scientists uncover new role of chromatin-modulatory enzyme during cancer development

Researchers at the University of North Carolina at Chapel Hill and the UNC Lineberger Comprehensive Cancer Center have uncovered a new role of a chromatin-modulatory enzyme, termed EZH2, during cancer development.

24 Feb 2022

New mutation may define a high-risk subtype of pediatric acute myeloid leukemia

A new mutation was identified in 9 percent of relapsed cases of pediatric acute myeloid leukemia (AML) that may define a new subtype of the disease.

17 Feb 2022

New high-risk subtype of relapsed pediatric AML revealed

When acute myeloid leukemia (AML) relapses, it is more difficult to treat and outcomes are dismal. Scientists at St. Jude Children's Research Hospital have discovered a mutation in pediatric AML that physicians can use to identify high-risk patients and better guide treatment.

17 Feb 2022

Hollings researcher receives grant to fight complications after pediatric bone marrow transplant

MUSC Hollings Cancer Center researcher Sophie Paczesny, M.D., Ph.D., recently received a four-year grant from the National Heart, Lung, and Blood Institute to investigate solutions to help doctors to fight complications after pediatric bone marrow transplantation (BMT).

12 Feb 2022

New approach to CAR T-cell therapy for B-cell cancers triples the targeted antigens on cancer cells

Researchers at University Hospitals Seidman Cancer Center and Case Western Reserve University have developed a novel approach to chimeric antigen receptor (CAR) T-cell therapy for B-cell cancers that triples the targeted antigens on cancer cells – a "back up" approach that promises to greatly reduce the potential for antigen escape currently found in CAR T therapies that solely target CD19.

2 Feb 2022

Lymphoma News and Research

Further Reading

Topologically designed antibody candidates for SARS-CoV-2 and cancer therapies

New implantable biotechnology produces and releases CAR-T cells for attacking tumors

Vaccine-induced antibody response to SARS-CoV-2 Omicron variant in patients with B cell malignancies with and without active B cell-targeted therapy

Trial reveals effectiveness of axi-cel as first-line treatment for high-risk lymphoma

Study finds high rates of cancer among men living with HIV

Study links phthalates to higher incidence of specific childhood cancers

Zentalis contributes $1 million to SU2C Catalyst program for research into targeted cancer therapeutics

Multi-institutional teams awarded grant support from the Starr Cancer Consortium

Most cancer patients develop antibodies after receiving COVID-19 vaccine, study shows

Study explores immune escape mutations caused by prolonged viral shedding in immunocompromised COVID-19 patient

New, highly promising strategy to overcome a key cause of cancer deaths

World Trade Center responders have increased levels of mutations that escalate blood cancer risk

Scientists uncover new role of chromatin-modulatory enzyme during cancer development

New mutation may define a high-risk subtype of pediatric acute myeloid leukemia

New high-risk subtype of relapsed pediatric AML revealed

Hollings researcher receives grant to fight complications after pediatric bone marrow transplant

New approach to CAR T-cell therapy for B-cell cancers triples the targeted antigens on cancer cells

MCL1 regulates neuronal autophagy, cell survival in Alzheimer's disease

Damon Runyon Cancer Research Foundation announces newest cohort of Fellows and Breakthrough Scientists

Study provides a new treatment option for patients with relapsed B-cell lymphoma

Everything you should know about lymphoma eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News